International Stem Cell Corp (ISCO): Operating Cash Flow
$8.0K
Year ended 2025-12-31
$369.0K
Trailing 12 months to 2026-06-30
-71.1%
3-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.0K | -38.5% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $13.0K | -98.6% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $929.0K | +179.8% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $332.0K | n/m | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | -$1.30M | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | -$341.0K | n/m | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | -$1.40M | n/m | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | -$1.08M | n/m | 2020-06-01, From 2018-01-01 |
| 2017-12-31 | -$2.14M | n/m | 2019-04-15, From 2017-01-01 |
| 2016-12-31 | -$4.20M | n/m | 2018-04-09, From 2016-01-01 |
| 2015-12-31 | -$4.12M | n/m | 2017-03-31, From 2015-01-01 |
| 2014-12-31 | -$6.42M | n/m | 2016-03-30, From 2014-01-01 |
| 2013-12-31 | -$5.64M | n/m | 2014-03-17, From 2013-01-01 |
| 2012-12-31 | -$6.69M | n/m | 2014-03-17, From 2012-01-01 |
| 2011-12-31 | -$6.96M | n/m | 2013-03-26, From 2011-01-01 |
| 2010-12-31 | -$6.95M | n/a | 2012-03-16, From 2010-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| International Stem Cell Corp (ISCO) | 2025-12-31 | $8.0K | -38.5% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | -$81.63M | n/m |
| Precigen, Inc. (PGEN) | 2025-12-31 | -$87.83M | n/m |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | -$163.58M | n/m |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | -$82.23M | n/m |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | -$172.33M | n/m |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | -$750.35M | n/m |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | -$10.74M | n/m |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | -$47.11M | n/m |
Compare ISCO, BIOA, PGEN, PRTA side by side · Screen every company in Pharmaceutical Preparations ↗